Visual outcomes of a new implantable phakic contact lens in patients with stable keratoconus

Farideh Doroodgar¹, Feizollah Niazi², Sana Niazi², Azad Sanginabadi³, Cyrus Alinia⁴

¹Negah Specialty Ophthalmic Research Center, Shahid Beheshti University of Medical Science, Tehran, Iran
²Shahid Beheshti University of Medical Sciences and Health Services, Chamran Highway, Daneshjoo Street, Tehran 1544914599, Iran
³Iran University of Medical Sciences and Health Services, Tehran 1544914599, Iran
⁴Department of Public Health, School of Public Health, Urmia University of Medical Sciences, Urmia, West Azerbaijan 1544914599, Iran

Correspondence to: Azad Sanginabadi. Iran University of Medical Sciences, Tehran 1544914599, Iran.
Sanginabadiazad@yahoo.com

Received: 2019-09-28        Accepted: 2020-03-08

Abstract

- AIM: To assess the efficacy, safety, stability and predictability of an implantable Phakic contact lens in patients with stable keratoconus.
- METHODS: The uncorrected and the best corrected visual acuity, defocus curve, contrast sensitivity, refraction and possible side effects were measured in 14 patients after utilizing implantable phakic contact lens (IPCL) to correct refractive errors. The result was assessed for more than 6mo.
- RESULTS: The mean preoperative spherical equivalent (SE) and astigmatism got changed from -6.94±2.79 DS and -4.24±1.42 DC to -0.23±0.43 DS and -1.05±0.49 DC, respectively at the last examination after 6mo. Before the preoperative the mean Snellen visual acuity was 0.18±0.10 logMAR. The mean uncorrected and the best corrected visual acuity got changed to 0.13±0.10 logMAR and 0.05±0.15 logMAR, respectively in 6mo. The mean safety indices were 1.11. There was no loss of visual acuity in any of the eyes and 22 eyes (78.5%) gained one or more lines. Twenty eyes (71.4%) were within 0.50 D and 27 (96.42%) were within ±1.00D of the desired SE refraction. There was a change in manifest refraction of -0.23±0.43 (range from -1.00 to +0.75) from the first week of surgery to 6mo. Contrast sensitivity got improvement value at 3 per degree (P<0.005) after Toric IPCL implantation. The total 6mo corneal endothelial cell loss (ECL) was <5%. Intraocular pressure (IOP) was 11.32±2.28 mm Hg after 6mo.

- CONCLUSION: The clinical consequences of the present study exhibit the efficacy, safety, and predictability of Toric implantable Phakic contact lens in the correction of myopia and myopic astigmatism related with stable keratoconus.
- KEYWORDS: keratoconus; implantable Phakic contact lens; visual acuity

DOI:10.18240/iar.2020.04.11


INTRODUCTION

Keratoconus is a non-inflammatory, progressive ectatic disorder related to irregular astigmatism and decrease corneal thickness[1]. Treatment of keratoconus relies upon the condition of the cornea ectasia and the degree of irregular astigmatism. In view of the biomechanical adjustments of the corneal collagen compound, it has been recommended to utilize collagen cross-linking (CXL) to end the progression of keratoconus, when progress is approved[2]. Soft contact lenses or glasses can be utilized in mild type and when the astigmatism increments and corneal distortion occurs, rigid gas permeable (RGP) lenses, intra-stromal ring sections or keratoplasty may be utilized to enhance the visual acuity[2-4]. The results of other treatment strategies like laser in situ keratomileusis (LASIK) appear to be capricious, as they may outcome in the further diminishing of the cornea and remainder refractive error[5-6]. Numerous studies[7-10] have utilized the phakic intraocular lenses (pIOLs) containing posterior chamber pIOLs to rectify refractive errors related to keratoconus, proposing a promising option. At present, it is one of the prosperous pIOLs, the implantable phakic contact lens (toric IPCL, Care Group India). The IPCL is similar to the soft contact lens, single piece posterior chamber phakic IOL, which can be inserted into eye through 2.8 mm incision. Sulcus placed posterior chamber phakic intraocular lens (IOL) which is made from reinforced hybrid acrylic material. Another type of lens that has a longer history is the implantable collamer lens (ICL) (STAAR Surgical Inc.). However, the potential reactions of this method remain to be explored. This
examination expected to evaluate the efficacy, safety, stability and predictability of the toric implantable Phakic contact lens in patients with stable keratoconus amid a 6mo follow up. As far as we know, this is the first study to examine the behavior of this posterior phakic IOL model.

**SUBJECTS AND METHODS**

This prospective study was conducted; the clinical outcomes of the implantable Phakic contact lens to correct refractive error were researched in 28 keratoconic eyes of 14 consecutive patients (Table 1). Patients who were over 23 years old were viewed as qualified to experience implantation of the Toric IPCL, intolerant to spectacles and contact lenses, had a steady refraction for at least one year and were happy with their vision when wearing glasses. Patients had no other general pathology and ocular and no more than stage III keratoconus pursuant to the Amsler-Krumeich classification[11].

**Inclusion Criteria** Accompanied corrected distance visual acuity (CDVA) of +0.4 logarithm of the minimum angle of resolution (logMAR) of 5/10 decimal or better, clear cornea, intraocular pressure (IOP) <20 mm Hg, normal ACD of at least 3 mm to the endothelium, a pupil diameter of less than 6.25 mm, width of angle greater than 30° and a pre-surgery endothelial cell count in association with age. Contact lens utilization was ceased for at least more than 3wk for RGP and one week for soft contact lens prior to any intervention.

**Exclusion criteria** contained introduction of autoimmune diseases and other ophthalmic issues, with the exception of keratoconus, for example, corneal opacification or scar, cataract, uveitis, diabetic retinopathy, glaucoma, central endothelial cell count of less than 2000 cells/mm² by specular microscopy (SP-8800; Konan, Nishinomiya, Japan), focal corneal thickness of under 450 mm [estimated by optical pachymetry (Pentacam-HR, Oculus Optikgerate, Wetzlar, Germany)] and ACD less than 3 mm from the endothelium to the anterior capsule measured by Orbscan IIZ (Orbscan, Bausch and Lomb, Rochester, New York, USA).

**Implantable IPCL Insertion Procedure** In this examination, the current V2 IPCL configuration was implanted. When started with topical anesthesia, dilating specialists were directed. For the Toric IPCL implantation, the surgeon (FD) denoted the zero horizontal axis amid slitlamp examination while the patient was lying upright to avoid cyclotorsion. IPCL, unlike the ICL, does not require a specific set. IPCL cartridge needs a 2.8 mm incision, marked to ensure proper orientation in the eye as it unfolds. Observe the IPCL for proper orientation in the cartridge, open the cartridge and injector fill the Cartridge with saline and HPMC, open the IPCL Container, gently hold the IPCL with McPherson Forceps near haptics, check the orientation of IPCL, Place the IPCL in the Cartridge, put the Cartridge in injector.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Refractive surgery, n (eyes)</td>
<td>14 (28)</td>
</tr>
<tr>
<td>Age, mean±SD</td>
<td>31.04±4.3</td>
</tr>
<tr>
<td>Range</td>
<td>23-36</td>
</tr>
<tr>
<td>Gender, n (%)</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>18 (64%)</td>
</tr>
<tr>
<td>Female</td>
<td>10 (35.7%)</td>
</tr>
<tr>
<td>Preoperative visual acuity (Range)</td>
<td></td>
</tr>
<tr>
<td>UCDVA</td>
<td>0.97±0.14 (0.7-1.2)</td>
</tr>
<tr>
<td>CDVA</td>
<td>0.18±0.10 (0.0-0.3)</td>
</tr>
<tr>
<td>Preoperative refractive error (spherical equivalent)</td>
<td>-3.50 -1.6 (-6.94±2.79)</td>
</tr>
<tr>
<td>Postoperative visual acuity</td>
<td></td>
</tr>
<tr>
<td>UCDVA</td>
<td>0.14±0.11</td>
</tr>
<tr>
<td>CDVA</td>
<td>0.05±0.16</td>
</tr>
<tr>
<td>Specular microscopy</td>
<td></td>
</tr>
<tr>
<td>Preoperative</td>
<td>2398.04±112.15</td>
</tr>
<tr>
<td>Postoperative</td>
<td>2337.36±112.39</td>
</tr>
</tbody>
</table>

UCDVA: Uncorrected distance visual acuity, CDVA: Correct distance visual acuity.

In a temporal approach, after injection of vasculosis, a small incision of the cornea was made at 2.8 mm, and the IPCL was injected through the incision into the anterior chamber and got slowly opened.

After injection of the Toric IPCL into the anterior chamber, the proper motion was accomplished with gentle posterior pressure and calm rotation of one or more clock hour. This move was rehashed for each of the four footplates, situating them under the iris plane. In the event that any change of the Toric IPCL was fundamental, it was expert with a gentle movement contacting the IPCL at the intersection of the optic and haptic. Aspiration and Irrigation of the viscoelastic materials were accomplished. An intraocular miotic (acetylcholine) was utilized to diminish the pupil size. The arrangement of the Toric IPCL was assessed by slitlamp examination at all visits post-surgically.

**Study Outcomes and Patient Follow-up** Post-surgical examinations were directed at a consistent follow-up program (baseline and in 1, 2, 4 and 6mo). The primary results parameters for this examination were cycloplegic refractions and manifest, uncorrected distance visual acuity (UCDVA) and CDVA. We assessed the accompanying: anterior and posterior segments assessment with dilated fundus evaluation, pre and postoperative inconveniences, endothelial cell count estimated on the central piece of the cornea by specular microscopy (SP-8800, IOP with Goldman applanation tonometry and non-contact tonometer Topcon CT-1P. Vault height was estimated objectively with ultrasound bio microscope (UBM, Sonomed, New York, USA) and subjectively (slit-lamp examination).
Contrast sensitivity test got accomplished under mesopic (3 cd/m²) and photopic (85 cd/m²) conditions utilizing the CVS1000 contrast sensitivity test (VectorVision, Greenville, SC). The tests were accomplished with the best glasses correction before the surgery and without correction after the surgery, utilizing a light level of 3 cd/m² after 10min of dark adaptation at a distance of 3 m. Testing was accomplished at 1, 3, 5, 6, 12 and 18 cycles for every degree (c/d). The defocus curve additionally gotten to assess the scope of utilitarian vision.

Statistical Analysis To statistically analyze the results, we utilized the SPSS programming (SPSS Statistics for Windows, V.23.0, 2013; IBM). The non-parametric Wilcoxon marked rank test was connected to decide the significant differences between the target outcomes before and after the implantation of Toric IPCL, for example, contrast sensitivity and the log MAR visual acuity, defocus curve. Given that these variables had ordinary dispersion, we reported the mean and SD to them. Ordinary factors were accounted for as mean and SD, and we sat the middle if circulations were skewed. We considered 5% level to discover the statistically significant differences in our analysis.

RESULTS Patient Population Table 1 illustrates patient’s demographics in summary. The mean spherical error was -4.89±3.96 D (range: -1.50 to -12.00 D), and the astigmatism was -4.24±1.42 D (range: -1.75 to -8.00 D). Toric IPCL was accomplished at the clinical investigational site from October 2017 to May 2018 in this group. Patients were followed up seven times after surgery at 1, 2, 4 and 6mo. All patients had a pre-surgery uncorrected distance visual acuity (UCDA) worse than 20/40 with 95% having uncorrected acuity limited to counting of fingers. In 6mo, post-surgically UCDVA was better than or equal to pre-surgically CDVA in 85% (24/28) of eyes, and UCDVA was incremented by ≥byremet, a 22 eyes (Table 2).

The preoperative CDVA and postoperative UCVA 6mo after toric IPCL operation is compared in Figure 1. Six months after postoperative, 71.42% of eyes were within ±0.50 D, and 96.42% were within ±1.0 D of endeavored correction. At the end of the follow-up, the mean vault height was 603±54.33 (range: 510-701) µm, and the IOP was 11.32±2.28 mm Hg.

Safety logMAR CDVA was 0.06±0.11, 0.04±0.15, 0.05±0.15 and 0.05±0.15 in 1, 2, 4 and 6mo after surgery with the IPCL, respectively. We found a significant difference between preoperative CDVA IPCL and all other follow-up (P<0.05, Wilcoxon signed-rank test). The safety index (mean postoperative CDVA/mean preoperative CDVA) was 1.09, 1.15, 1.11 and 1.11 at 1, 2, 3 and 6mo after operation with the IPCL, respectively.

Treatment Effectiveness Uncorrected distance visual acuity 6mo after postoperative for the entire subjects was ≥20/20 in 46.42% of eyes and ≥20/40 in 100% of eyes. The uncorrected visual outcomes in this ‘all eyes’ group must be interpreted in the context: only 50% of these eyes had CDVA of ≥20/20 at the baseline. 6mo after postoperative, UCDVA was equal to or better than preoperative CDVA in 78.57% (22/28) of eyes.

Predictability of Manifest Refraction (attempted vs achieved) The following outcomes are relied upon to give a more exact appraisal of refraction exactness than the postoperative mean refractive spherical equivalent (MRSE) results. Six months after postoperative, 71.42% of eyes were inside ±0.50 D, and 96.42% were inside ±1.0 D of endeavored correction. The differences in SE, cylinder and sphere were statistically significant between preoperative and 1mo postoperatively. These differences remained stable for 6mo and 2, 4 and 6mo after operation (Figure 2). Even though emmetropia was the targeted postoperative refraction in all patients, small hyperopic and myopic deviations were found after IPCL implantation.

### Table 2 Manifest refraction, the toric implantable Phakic contact lens

<table>
<thead>
<tr>
<th>Cylinder</th>
<th>Preoperative n/N (%)</th>
<th>Postoperative after 1year n/N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤-1.50</td>
<td>0/28 (0)</td>
<td>≤-1.50</td>
</tr>
<tr>
<td>≤-3.50</td>
<td>11/28 (39)</td>
<td>≤-3.00</td>
</tr>
<tr>
<td>≤-5.00</td>
<td>21/28 (75)</td>
<td>16/28 (57)</td>
</tr>
<tr>
<td>≤-7.00</td>
<td>27/28 (96)</td>
<td>27/28 (96)</td>
</tr>
<tr>
<td>≤-8.00</td>
<td>28/28 (100)</td>
<td>28/28 (100)</td>
</tr>
<tr>
<td>Mean±SD</td>
<td>-4.24±1.45</td>
<td>-4.89±2.55</td>
</tr>
<tr>
<td>Sphere</td>
<td>≤-3.00</td>
<td>≤-3.00</td>
</tr>
<tr>
<td>n/N (%)</td>
<td>8/28 (28)</td>
<td>28/28 (100)</td>
</tr>
</tbody>
</table>

n: Number of subjects; N: Total subjects.

Figure 1 A comparison of preoperative best corrected visual acuity and postoperative uncorrected distance visual acuity 6m after toric IPCL.
Defocus Curve  Figure 3 demonstrates the logMAR visual acuity under defocus curve of +2, +1, 0, -1, -2, and -3 D in postoperative and preoperative periods in a non-cycloplegic situation. The contrasts between the estimations of binocular distance corrected defocus bend in the examination showed significant differences in logMAR visual acuity at the defocus bend levels of +1, 0 and -1 D, yet no significant differences were seen at the defocus bend levels of +2, -2, and -3 D.

Contrast Sensitivity  Figure 4 demonstrates the mesopic contrast sensitivity outcomes, which exhibit no loss of contrast at any spatial frequency and a measurably noteworthy change conversely an incentive at 3 and 1.5 for each degree. Furthermore, photopic contrast sensitivity (Figure 5B) exhibited a critical change, interestingly, an incentive at 3 for each degree incomparable mesopic conditions.

Vaulting the IPCL  Figure 5 shows the adjustment in vault between successive estimations in various times. Objective and subjective vaults were steady after IPCL implantation in 2mo.

DISCUSSION
This examination exhibited the visual results of Toric IPCL implantation in stable keratoconus with a 6-month follow-up. This examination assessed efficacy, predictability, safety and stability of this system in patients with stable keratoconus. These discoveries in conjunction with excellent outcomes for refractive signs that influence the quality of life[12] empower Toric ICL to be the primary suggested phakic IOL approved in the USA for patients younger than 60 years[13]. Posterior chamber phakic IOLs can be viewed as a safe procedure to treat refractive errors in keratoconic patients with better restorative results, due to position of the IOL behind the iris[14-15]. Toric IPCL is accessible with spherical powers from +15.0 to -30.0 D for adjustment of refractive error and an astigmatism power to 10.00 D that wide range is viewed as an awesome benefit at show. The visual acuity test is bitten by bit turning into the gold standard level for the appraisal of vision, giving exclusively a confined amount of information under artificial conditions (Table 2). Contrast sensitivity exhibited an assortment of visual performance information under real conditions. This inspired us to gain ground around there of medicine. To the best of our knowledge (Web of Science and PubMed), this is the first investigation of Toric IPCL in patients with stable keratoconus that focuses on visual function (contrast sensitivity, visual acuity, defocus curve and refraction). No decrease in contrast sensitivity was seen at any spatial frequency. Photopic and mesopic contrast sensitivity demonstrated a statistically significant betterment in value at 3 per degree. There is no totally consummate test for contrast sensitivity[16]. We picked this strategy, since it is easy to understand, time-saving and accessible, and it diminishes the examiners’ mistake. Notwithstanding, in spite of the considerable number of contemplations, the test result was impacted by numerous different components that enhanced contrast sensitivity, other than refractive correction of auxiliary system, one-time CXL with riboflavin and UV A, enhance aberrations and contrast sensitivity[17-18]. We had three patients with pre-surgery astigmatism more noteworthy than six (Table 2). A few subjects of s would do well to resilience to myopic defocus curve (-1), which appears to be identified with the remaining refraction in these subjects.

The chief possibly complications after IPCL and ICL implantation are cataract formation, 15 intense increments in IOP and night vision disorders[19]. Anterior segment anatomy assessment with new propelled advances and consideration of the surgeon to notice signs before operation permits the choice of the best possible size and diminishes likely complications[20]. We believe that before operation, patients with shallower ACD and older patients and larger White to White ought to be made mindful of the likelihood of complication after
this technique\[21\]. Cataract surgery in keratoconus prompts resurgence of visual acuity, particularly by various means, for example, Toric multifocal lenses\[22\]. Conceivable hazard factors for night vision unsettling influences after ICL are White to White measurement of the cornea, distinction between the optic zone width and the mesopic pupil size, corona and toxicity of the ICL and glare\[23\] but fortunately, the new lenses make it possible to order lenses with larger optics, which minimizes the possibility of light transmission and glare in large pupils. The pre-surgery and postoperative are comprised of a complete ophthalmic examination.

The IPCL implantation is a plausible manage with less infringement in visual function since it doesn’t change the curvature ratios between the front and back corneas\[24\]. In this regard, albeit a few methodologies may demonstrate slightly better results for UCVA and refractive consistency, toric IPCL implantation indicated dependable outcomes like those of bioptics. A single-step method with IPCL implantation may maintain a strategic distance from the potential complications for elective second surgeries. A pattern toward reduction of corneal transplantation for keratoconus looking at two changed periods was accounted for by some studies\[25\]. It is a guarantee that appears to be identified with contemporary administration modalities in prior recognition of movement and medications of keratoconus.

The clinical results of the present examination exhibit the efficacy, safety and predictability of toric implantable Phakic contact lens in patients with stable keratoconus. One of the limitations of this study was a small number of patients and a short follow-up period that required further studies and a large number of patients in future studies.

ACKNOWLEDGEMENTS

Conflicts of Interest: Doroodgar F, None; Niazi F, None; Niazi S, None; Sanginabadi A, None; Alinia C, None.

REFERENCES

1 Alió JL. What is keratoconus? A new approach to a not so rare disease. Keratoconus. Cham: Springer International Publishing 2016:3-5.
16 Maniglia M, Thurman SM, Seitz AR, Davey PG. Effect of varying levels of glare on contrast sensitivity measurements of young healthy individuals under photopic and mesopic vision. *Front Psychol* 2018;9:899.

266